3/24
01:02 pm
stok
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally [Yahoo! Finance]
Low
Report
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally [Yahoo! Finance]
3/20
05:17 pm
stok
Stoke Therapeutics (STOK) had its price target raised by Canaccord Genuity Group Inc. from $36.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Stoke Therapeutics (STOK) had its price target raised by Canaccord Genuity Group Inc. from $36.00 to $60.00. They now have a "buy" rating on the stock.
3/19
08:43 am
stok
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
Medium
Report
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
3/18
08:40 am
stok
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
Medium
Report
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
3/17
05:12 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Medium
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
3/17
08:43 am
stok
Stoke Therapeutics (STOK) had its price target raised by Wedbush from $36.00 to $38.00. They now have an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (STOK) had its price target raised by Wedbush from $36.00 to $38.00. They now have an "outperform" rating on the stock.
3/17
08:01 am
stok
Stoke Therapeutics (STOK) had its price target raised by Needham & Company LLC from $35.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Stoke Therapeutics (STOK) had its price target raised by Needham & Company LLC from $35.00 to $40.00. They now have a "buy" rating on the stock.
3/6
07:03 pm
stok
How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline [Yahoo! Finance]
Medium
Report
How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline [Yahoo! Finance]
3/4
05:06 pm
stok
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Low
Report
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
3/4
07:51 am
stok
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs [Yahoo! Finance]
Low
Report
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs [Yahoo! Finance]
2/25
06:24 am
stok
Stoke Therapeutics (STOK) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Stoke Therapeutics (STOK) was upgraded by Wolfe Research to "strong-buy".
2/24
04:01 pm
stok
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Neutral
Report
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2/23
06:01 pm
stok
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
2/18
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
High
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2/15
10:13 am
stok
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit [Yahoo! Finance]
Low
Report
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit [Yahoo! Finance]
2/11
07:30 am
stok
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Low
Report
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
2/7
06:18 am
stok
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/5
05:03 am
stok
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
2/4
04:27 pm
stok
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Medium
Report
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
2/4
04:01 pm
stok
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
1/27
02:22 pm
stok
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA [Yahoo! Finance]
Low
Report
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA [Yahoo! Finance]
1/27
02:05 pm
stok
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Low
Report
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
1/16
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
1/15
09:15 am
stok
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
Medium
Report
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
1/12
09:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.